All News

PEE readership survey v. 2

Myth vs. Reality: The American healthcare system needs a makeover. That requires policies based on accurate information about how our country’s system compares to others’. To start, we must separate fact from fiction.

PEE Readership Survey 2007

A new bill says HHS has to negotiate Medicare drug prices with pharma companies. It won't work-but that's not the biggest thing wrong with it.

Drug giant's new style features brains over brawn.

Physicians still slow to restrict prescribing data from sales reps as New Hampshire case goes to trial.

Unbranded campaign with American Heart Association kicks off with much fanfare.

PEE Reader Survey Jan 2007

FTC is looking to ban reverse-payment settlements and pharma must tread with caution.

Kindler's Strategic Direction Is Neither, Say Cranky Analysts

Consumers still aren't happy, but industry calls FDA's addition to PDUFA 'an important new step.'

Novartis' upcoming anti-hypertension combo and campaign target noncompliance.

Consumers say no, and they're watching which companies are naughty or nice.

PEE Advertiser Study - Clinical

PEE Advertiser Research Study

Biotech companies, for years at the mercy of their deep-pocketed pharma partners, are finally holding the strings.

Cardio competitors team up to find new ways of preventing heart attacks.

(And the Times' front-page pounding had nothing to do with it.)

Multi-company campaign hopes to cast clinical trial participants as 'heroes.'

Government report paints picture of ineffectual FDA buried by avalanche of ads.

SUPPLEMENTS

Pharma faces a wide array of pressing issues-almost too many to think about comfortably-from drug safety and the industry's image to intellectual property in emerging markets and the overall usefulness of marketing. To remain effectively focused on strategy, industry executives must find relations between all the individual issues and group them into larger themes. Pragmatically, we all know this is essential.

Pharma's next big challenge is simple: Rebuild its broken business model. But between expiring patents and dry pipelines, pricing wars and safety woes, a beleaguered FDA, a bloodthirsty OIG, and Dems on parade, many companies are just trying to steer clear of icebergs.

Analysts say Times' accusatory articles on Zyprexa are nothing to get excited about.

FDA's revisions to guidelines on expanding access to experimental drugs intensify an already murky issue for pharma.

At its annual pipeline debut, the company introduced its own CETP-inhibitor--with doubts.

Studies show pharma has succeeded at raising disease awareness. Brand loyalty, though, has suffered.

Recent drug trials, and marketing efforts in Europe, for Acomplia indicate that Sanofi-Aventis may be seeking a life-threatening indication for its much-hyped weight-loss drug.